Soligenix

Soligenix, based in Princeton and listed on Nasdaq, develops treatments for rare diseases and biodefence. Its lead cancer programme is HyBryte (synthetic hypericin), a photosensitiser applied to skin lesions and activated with visible rather than ultraviolet light, for early-stage mycosis fungoides, the commonest form of cutaneous T-cell lymphoma; the FLASH phase 3 trial met its primary endpoint in 2020 and a confirmatory trial, FLASH2, followed at the FDA's request. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.